Abstract: This composite material blade, which is formed using a composite material including reinforcing fibers and resin, and which has a positive pressure surface and a negative pressure surface, is provided with a ventral part, being the part on the positive pressure surface side in a blade thickness direction, which is the direction joining the positive pressure surface and the negative pressure surface, a dorsal part, being the part on the negative pressure surface side in the blade thickness direction, and a metal shield portion which is provided on the leading edge side, being the upstream side in a flow direction in which a fluid flows, wherein: the metal shield portion includes a main body portion provided on the leading edge side, and an embedded portion which is provided on the trailing edge side, being the downstream side in the flow direction, of the main body portion, and which is provided between the ventral part and the dorsal part; and the plate thickness of the metal shield portion in the blade thick

Abstract: A braking control device for controlling braking of a host vehicle. For a state in which a host vehicle is stopped in an intersection by automatic emergency braking and an oncoming vehicle is approaching in an oncoming lane, the host vehicle prohibits secondary braking is prohibited in, flashes a hazard lamp, and prohibits an idling stop. For a state in which it is determined in that the vehicle is stopped and it is determined in that it is safe for the vehicle to start moving, the host vehicle releases stop maintenance braking.

Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.

Abstract: A vehicle brake system, including: a first-braking-force control mechanism configured to control a first braking force, a second-braking-force control mechanism configured to control a second braking force, an abnormal-state detecting device configured to detect whether the first-braking-force control mechanism is in an abnormal state, a pseudo-abnormal-state detecting device configured to detect whether the first-braking-force control mechanism is in a pseudo abnormal state in which the first-braking-force control mechanism is suspected to be in the abnormal state, and a controller including a pseudo abnormal state controller configured to control the second-braking-force control mechanism in an operating state of the first-braking-force control mechanism so as to control the second braking force when the pseudo-abnormal-state detecting device detects that the first-braking-force control mechanism is in the pseudo abnormal state.

Abstract: The present invention relates to genetically engineered cell populations derived from an immortalised/cancerous cell that do not express MHC class I molecules but that are modified to express membrane-bound IL-15, membrane-bound 4-1 BBL ligand, and at least one other membrane bound molecule, such as an interleukin or anti-CD3 antibody. The co-culture of said cells with a population of immune cells results in the activation and expansion of at least one subpopulation of immune cells. Expanded populations of NK cells derived from the co-culture of a mixed cell culture with the stimulatory cell lines may be used in methods of treating cancer or an infectious disease. In a separate embodiment, a plurality of nucleic acids for use in preparing the engineered cell population are provided.

Abstract: The present invention provides compositions comprising a protein expression blocker or PEBL comprising a target-binding molecule and localizing domain, and methods of using such compositions in cancer therapy. PEBLs are useful as a blockade of expression of target surface receptors (peptides or antigens) in immune cells. Also provided herein are CD3/TCR??-deficient T cells and CD3/TCR??-deficient chimeric antigen receptor T cells that express such PEBLs.

Abstract: The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.

Abstract: The present invention provides compositions comprising a protein expression blocker or PEBL comprising a target-binding molecule and localizing domain, and methods of using such compositions in cancer therapy. PEBLs are useful as a blockade of expression of target surface receptors (peptides or antigens) in immune cells. Also provided herein are CD3/TCR??-deficient T cells and CD3/TCR??-deficient chimeric antigen receptor T cells that express such PEBLs.

Abstract: The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.

Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.

Abstract: The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.

Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.

Abstract: A hedge trimmer may include a housing provided with a handle configured to be gripped by a user, a pair of shear blades extending forward from the housing; a motor housed in the housing and configured to drive at least one of the pair of shear blades; and an electric circuit unit housed in the housing and configured to control power supplied to the motor. The handle may be provided at an upper portion of the housing in rear of the motor, and the electric circuit unit may be located under the handle in the rear of the motor.

Abstract: The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.

Abstract: The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule CI for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.

Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.

Abstract: The present invention relates to genetically engineered cell populations derived from an immortalised/cancerous cell that do not express MHC class I molecules but that are modified to express membrane-bound IL-15, membrane-bound 4-1 BBL ligand, and at least one other membrane bound molecule, such as an interleukin or anti-CD3 antibody. The co-culture of said cells with a population of immune cells results in the activation and expansion of at least one subpopulation of immune cells. Expanded populations of NK cells derived from the co-culture of a mixed cell culture with the stimulatory cell lines may be used in methods of treating cancer or an infectious disease. In a separate embodiment, a plurality of nucleic acids for use in preparing the engineered cell population are provided.

Abstract: A hydroponic system (1) is provided with a light-collecting apparatus (3) having a pair of reflecting plates (31a) that are vertically arranged in parallel with a culture surface (23) of a culture panel (21) of a hydroponic unit (2). During a process in which natural light taken from a light-collecting opening (30) propagates while repeatedly reflected by opposing reflecting surfaces of a reflecting plates (31a), by allowing seedlings p that are transplanted into the culture panel (21) to be irradiated with the light through a light-emitting hole (32) bored in the reflecting plate (31a), a culture object can be grown efficiently at a low cost by taking natural light from the outside.

Abstract: A hedge trimmer may include a housing provided with a handle configured to be gripped by a user, a pair of shear blades extending forward from the housing; a motor housed in the housing and configured to drive at least one of the pair of shear blades; and an electric circuit unit housed in the housing and configured to control power supplied to the motor. The handle may be provided at an upper portion of the housing in rear of the motor, and the electric circuit unit may be located under the handle in the rear of the motor.

Abstract: The present invention provides compositions comprising a protein expression blocker or PEBL comprising a target-binding molecule and localizing domain, and methods of using such compositions in cancer therapy. PEBLs are useful as a blockade of expression of target surface receptors (peptides or antigens) in immune cells. Also provided herein are CD3/TCR??-deficient T cells and CD3/TCR??-deficient chimeric antigen receptor T cells that express such PEBLs.